表紙
市場調査レポート

乾癬性関節炎:パイプライン製品の分析

Psoriatic Arthritis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232834
出版日 ページ情報 英文 252 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
乾癬性関節炎:パイプライン製品の分析 Psoriatic Arthritis - Pipeline Review, H1 2016
出版日: 2016年05月18日 ページ情報: 英文 252 Pages
概要

乾癬性関節炎(PA)は、乾癬に罹っている人の一部に合併して見られる関節炎です。手足の指の腫れ、足の痛み、腰痛などの症状が見られます。危険因子として、年齢、家族歴、乾癬患者が挙げられます。治療には、NSAID(非ステロイド性抗炎症薬)、免疫抑制剤、外科手術などが含まれます。

当レポートでは、乾癬性関節炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

乾癬性関節炎の概要

治療薬の開発

  • パイプライン製品の概要

乾癬性関節炎:企業で開発中の治療薬

乾癬性関節炎:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

乾癬性関節炎:企業で開発中の製品

乾癬性関節炎の治療薬開発に従事している企業

  • AbbVie Inc.
  • AbGenomics International, Inc.
  • Alder Biopharmaceuticals Inc.
  • Alteogen Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • BIOCAD
  • Biocon Limited
  • Bionovis SA
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Forward Pharma A/S
  • Genor BioPharma Co., Ltd.
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Kadmon Corporation, LLC
  • Kineta, Inc.
  • Mabion SA
  • Momenta Pharmaceuticals, Inc.
  • Morphotek, Inc.
  • Mycenax Biotech Inc.
  • Novo Nordisk A/S
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Swedish Orphan Biovitrum AB
  • Therapeutic Proteins International, LLC
  • UCB S.A.
  • Valeant Pharmaceuticals International, Inc.
  • Vitae Pharmaceuticals, Inc.
  • Xbrane Biopharma AB

乾癬性関節炎:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

乾癬性関節炎:最近のパイプライン動向

乾癬性関節炎:休止中のプロジェクト

乾癬性関節炎:開発が中止された製品

乾癬性関節炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8010IDB

Summary

Global Markets Direct's, 'Psoriatic Arthritis - Pipeline Review, H1 2016', provides an overview of the Psoriatic Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis
  • The report reviews pipeline therapeutics for Psoriatic Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Psoriatic Arthritis therapeutics and enlists all their major and minor projects
  • The report assesses Psoriatic Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Psoriatic Arthritis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Psoriatic Arthritis Overview
    • Therapeutics Development
  • Pipeline Products for Psoriatic Arthritis - Overview
  • Psoriatic Arthritis - Therapeutics under Development by Companies
  • Psoriatic Arthritis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Psoriatic Arthritis - Products under Development by Companies
  • Psoriatic Arthritis - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • AbGenomics International, Inc.
    • Alder Biopharmaceuticals Inc.
    • Alteogen Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • BIOCAD
    • Biocon Limited
    • Bionovis SA
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Celltrion, Inc.
    • Coherus BioSciences, Inc.
    • Eli Lilly and Company
    • Epirus Biopharmaceuticals, Inc.
    • Forward Pharma A/S
    • Genor BioPharma Co., Ltd.
    • Innovent Biologics, Inc.
    • Johnson & Johnson
    • Kadmon Corporation, LLC
    • Kineta, Inc.
    • Mabion SA
    • Momenta Pharmaceuticals, Inc.
    • Morphotek, Inc.
    • Mycenax Biotech Inc.
    • Novo Nordisk A/S
    • Oncobiologics, Inc.
    • Panacea Biotec Limited
    • Pfizer Inc.
    • Sandoz International GmbH
    • Swedish Orphan Biovitrum AB
    • Therapeutic Proteins International, LLC
    • UCB S.A.
    • Valeant Pharmaceuticals International, Inc.
    • Vitae Pharmaceuticals, Inc.
    • Xbrane Biopharma AB
  • Psoriatic Arthritis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept - Drug Profile
    • AbGn-168H - Drug Profile
    • AbGn-168H2 - Drug Profile
    • ABT-122 - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • anakinra (recombinant) - Drug Profile
    • apremilast - Drug Profile
    • bimekizumab - Drug Profile
    • brodalumab - Drug Profile
    • certolizumab pegol biosimilar - Drug Profile
    • clazakizumab - Drug Profile
    • COVA-322 - Drug Profile
    • dalazatide - Drug Profile
    • dimethyl fumarate - Drug Profile
    • DNX-114 - Drug Profile
    • etanercept - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • golimumab - Drug Profile
    • golimumab biosimilar - Drug Profile
    • golimumab biosimilar - Drug Profile
    • golimumab biosimilar - Drug Profile
    • guselkumab - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • INV-17 - Drug Profile
    • itolizumab - Drug Profile
    • ixekizumab - Drug Profile
    • KANAb-071 - Drug Profile
    • KD-025 - Drug Profile
    • liraglutide (recombinant) - Drug Profile
    • risankizumab - Drug Profile
    • tofacitinib citrate - Drug Profile
    • ustekinumab biosimilar - Drug Profile
    • ustekinumab biosimilar - Drug Profile
    • VALBRO-03 - Drug Profile
    • VTP-43742 - Drug Profile
  • Psoriatic Arthritis - Recent Pipeline Updates
  • Psoriatic Arthritis - Dormant Projects
  • Psoriatic Arthritis - Discontinued Products
  • Psoriatic Arthritis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Psoriatic Arthritis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Psoriatic Arthritis - Pipeline by AbbVie Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Alteogen Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Amgen Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by AstraZeneca Plc, H1 2016
  • Psoriatic Arthritis - Pipeline by BIOCAD, H1 2016
  • Psoriatic Arthritis - Pipeline by Biocon Limited, H1 2016
  • Psoriatic Arthritis - Pipeline by Bionovis SA, H1 2016
  • Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Psoriatic Arthritis - Pipeline by Celgene Corporation, H1 2016
  • Psoriatic Arthritis - Pipeline by Celltrion, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H1 2016
  • Psoriatic Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H1 2016
  • Psoriatic Arthritis - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Johnson & Johnson, H1 2016
  • Psoriatic Arthritis - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Psoriatic Arthritis - Pipeline by Kineta, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Mabion SA, H1 2016
  • Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Morphotek, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Novo Nordisk A/S, H1 2016
  • Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Panacea Biotec Limited, H1 2016
  • Psoriatic Arthritis - Pipeline by Pfizer Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H1 2016
  • Psoriatic Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H1 2016
  • Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H1 2016
  • Psoriatic Arthritis - Pipeline by UCB S.A., H1 2016
  • Psoriatic Arthritis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016
  • Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Psoriatic Arthritis Therapeutics - Recent Pipeline Updates, H1 2016
  • Psoriatic Arthritis - Dormant Projects, H1 2016
  • Psoriatic Arthritis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Psoriatic Arthritis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top